Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical

Press ReleaseNicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China ZERVIATE (cetirizine ophthalmic solution), 0.24% was non-inferior to comparator

Related Keywords

Mexico , United States , Valbonne , Provence Alpes Côd Azur , France , Paris , France General , United Kingdom , China , South Korea , Chinese , Gavin Spencer , Enregistrement Universel , Pharma Bio , Kepler Cheuvreux Damien Choplain , States Europe , Sophia Antipolis , Santen Pharmaceutical Co Ltd Of Japan , Head Of Corporate Development , Lifesci Advisors , Eyevance Pharmaceuticals , Edison Investment Research Pooya Hemami London , Garnier Co Dylan Van Haaften Paris , Partner Ocumension Obtains Positive Phase , Trial Results , Euronext Paris , Chinese Phase , New Drug Application , Chief Business Officer , Far East , Ocumension Therapeutics , Southeast Asian , Samil Pharmaceutical , Laboratorios Grin , South East Asian , Mid Caps , Investment Research , Pooya Hemami , New York , Damien Choplain , Vice President , Chief Business , Corporate Development , Sci Advisors , French Autorit , Des March , Nicox , Partner , Cumension , Btains , Positive , Hase , Linical , Trial , Results , Erviate ,